for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Patrys Limited

PAB.AX

Latest Trade

0.04AUD

Change

-0.00(-2.44%)

Volume

2,472,837

Today's Range

0.04

 - 

0.04

52 Week Range

0.02

 - 

0.06

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.04
Open
0.04
Volume
2,472,837
3M AVG Volume
186.78
Today's High
0.04
Today's Low
0.04
52 Week High
0.06
52 Week Low
0.02
Shares Out (MIL)
1,815.47
Market Cap (MIL)
76.80
Forward P/E
--
Dividend (Yield %)
--

Next Event

Patrys Ltd Annual Shareholders Meeting

Latest Developments

更多

Patrys Expects Delay In Getting Components For Fermentation Media To Make PAT-DX1

Patrys Announces $7.3M Capital Raising

Patrys Says First Patent Granted For Deoxymab-Nanoparticles

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Patrys Limited

Patrys Limited is an Australia-based company, which is engaged in the development of antibody therapies for the treatment of cancer. The Company is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The Company has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The Company is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.

Industry

Biotechnology & Drugs

Contact Info

C:/ Leydin Freyer

Australia, L 4 100 Albert Rd

SOUTH MELBOURNE, VIC

3205

Australia

+61.3.96703273

http://www.patrys.com/

Executive Leadership

John Douglas Read

Independent Non-Executive Chairman of the Board

James A. Campbell

Chief Executive Officer, Managing Director, Director

Michael Stork

Non-Executive Deputy Chairman of the Board

Melanie Jaye Leydin

Company Secretary

Pamela M. Klein

Non-Executive Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
57.38
Price To Book (MRQ)
6.33
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-47.95
Return on Equity (TTM)
-44.48

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up